Clinical Trials
11 trialsNCT00038194 2018-10-31
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00331409 2017-10-26
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
OHSU Knight Cancer Institute
Phase 2 Completed
NCT00251225 2017-08-09
A Study of Imatinib and Docetaxel in Prostate Cancer
University of Pittsburgh
Phase 2 Completed
NCT01316458 2017-06-01
Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy
Novartis
Phase 2 Completed
NCT00427999 2016-11-21
INV342
Novartis
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00500110 2015-04-28
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00424385 2014-07-21
Study Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-independent Prostate Cancer (AIPC)
Oncology Specialists, S.C.
Phase 1 Completed
NCT00193258 2013-01-31
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00084825 2012-10-26
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00080678 2012-10-12
Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Phase 2 Completed